Table 1.
MONODO patient ID | |||||||||
---|---|---|---|---|---|---|---|---|---|
01 | 02 | 03 | 04 | 05 | 06 | 07 | 08 | ||
Plasma HIV‐1 RNA (copies/mL) | Baseline | < 20 | < 20 | < 20 | < 20 | < 20 | < 20 | < 20 | < 20 |
Week 4 | < 20 | < 20 | < 20 | < 20 | < 20 | < 20 | < 20 | < 20 | |
Week 8 | < 20 | < 20 | < 20 | < 20 | < 20 | < 20 | < 20 | < 20 | |
Week 12 | < 20 | < 20 | < 20 | < 20 | < 20 | < 20 | < 20 | < 20 | |
Week 16 | < 20 | < 20 | < 20 | < 20 | < 20 | < 20 | < 20 | NAa | |
Week 20 | < 20 | < 20 | < 20 | < 20 | < 20 | < 20 | < 20 | NAa | |
Week 24 | < 20 | < 20 | < 20 | < 20 | < 20 | < 20 | < 20 | NAa | |
CSF HIV‐1 RNA (copies/mL) | Baseline | NAb | < 20 | NAb | NAb | NAb | NAb | NAb | NAb |
Week 24 | < 20 | < 20 | < 20 | 28 | < 20 | NA | < 20 | NAa | |
Seminal fluid HIV‐1 RNA (copies/mL)e | Baseline | < 40 | NAc | NAc | < 40 | < 40 | < 40 | NAc | < 80 |
Week 24 | < 80 | NAc | NAc | < 40 | < 40 | < 40 | NAc | NAa | |
Total HIV‐1 DNA in PBMCs (DNA copies/106 genomic equivalents)f | Baseline | NAd | 170.9 | NAd | 205.8 | 185.6 | 248.6 | 67.2 | NAd |
Week 24 | NAd | 108.9 | NAd | 279.1 | 72.0 | 483.3 | 145.5 | NAa | |
DTG concentration at week 24 (ng/mL) | Plasma | 367 | 2088 | 1707 | 2104 | 2834 | 145 | 3100 | NAa |
CSF | 9 | 10.4 | 6.1 | 5.4 | 10.4 | NA | 12.6 | NAa | |
Seminal fluid | 0 | NAc | NAc | 84 | 205 | 0 | NAc | NAa |
ID, identification; NA, not available; CSF, cerebrospinal fluid; PBMCs, peripheral blood mononuclear cells.
Patient discontinued the study at week 12.
Lumbar puncture optional at baseline.
Female or transgender: no sperm sample possible.
Missing data.
The limit of quantification in seminal fluid is 40 copies/mL because of sample dilution.
HIV‐1 DNA and the single‐copy host gene C‐C chemokine receptor type 5 (CCR5) were quantified by digital droplet polymerase chain reaction in parallel. Cell counts are displayed as genomic equivalents as defined by two CCR5 copies per genomic equivalent (cell).